Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Elahe Karimi-Shahrbabak"'
Autor:
Zahra Yari, Zahra Naser-Nakhaee, Elahe Karimi‐Shahrbabak, Makan Cheraghpour, Mehdi Hedayati, Seyede Marjan Mohaghegh, Shahrzad Ommi, Azita Hekmatdoost
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 13, Iss 1, Pp 1-11 (2021)
Abstract Background Regarding the increasing prevalence of cardiometabolic abnormalities, and its association with non-communicable chronic diseases, providing preventive and therapeutic strategies is a priority. A randomized placebo-controlled study
Externí odkaz:
https://doaj.org/article/1cdb98f23a844097a9b091f82a5aa71e
Autor:
Yamna Ali, Pierre-Philippe Piche-Renaud, Elahe Karimi-Shahrbabak, Daniel S. Farrar, Sarah Abu Fadaleh, Sharon Burey, Shaun K. Morris
Publikováno v:
Vaccine. 41:3058-3065
Autor:
Pierre-Philippe Piché-Renaud, Elahe Karimi-Shahrbabak, Sarah Abu Fadaleh, Daniel Farrar, Julia Orkin, Michelle Science, Shaun Morris
Publikováno v:
Canada Communicable Disease Report. 49:127-132
Autor:
Pierre-Philippe Piché-Renaud, Elahe Karimi-Shahrbabak, Sarah Abu Fadaleh, Daniel Farrar, Julia Orkin, Michelle Science, Shaun Morris
Publikováno v:
Relevé des maladies transmissibles au Canada. 49:143-149
Autor:
Makan Cheraghpour, Zahra Yari, Azita Hekmatdoost, Mehdi Hedayati, Seyede Marjan Mohaghegh, Zahra Naser-Nakhaee, Shahrzad Ommi, Elahe Karimi-Shahrbabak
Publikováno v:
Diabetology & Metabolic Syndrome
Diabetology & Metabolic Syndrome, Vol 13, Iss 1, Pp 1-11 (2021)
Diabetology & Metabolic Syndrome, Vol 13, Iss 1, Pp 1-11 (2021)
Background Regarding the increasing prevalence of cardiometabolic abnormalities, and its association with non-communicable chronic diseases, providing preventive and therapeutic strategies is a priority. A randomized placebo-controlled study was cond
Autor:
Zahra Yari, Shahrzad Ommi, Makan Cheraghpour, Mehdi Hedayati, Elahe Karimi-Shahrbabak, Seyed Moayed Alavian, Azita Hekmatdoost, Hossein Imani
Publikováno v:
Phytotherapy research : PTR. 33(8)
This study aimed to evaluate the effects of hesperidin on nonalcoholic fatty liver disease (NAFLD) characteristics. In this randomized, double-blind, controlled clinical trial, 50 NAFLD patients were supplemented with either 1-g hesperidin capsule or
Autor:
Yari, Zahra1 (AUTHOR), Naser-Nakhaee, Zahra1 (AUTHOR), Karimi‐Shahrbabak, Elahe2 (AUTHOR), Cheraghpour, Makan3 (AUTHOR) Bio_makan@yahoo.com, Hedayati, Mehdi4 (AUTHOR), Mohaghegh, Seyede Marjan5 (AUTHOR), Ommi, Shahrzad6 (AUTHOR), Hekmatdoost, Azita1 (AUTHOR) Azita.Hekmatdoost@cw.bc.ca
Publikováno v:
Diabetology & Metabolic Syndrome. 1/6/2021, Vol. 13 Issue 1, p1-11. 11p.
Autor:
Cheraghpour, Makan, Imani, Hossein, Ommi, Shahrzad, Alavian, Seyed Moayed, Karimi‐Shahrbabak, Elahe, Hedayati, Mehdi, Yari, Zahra, Hekmatdoost, Azita, Karimi-Shahrbabak, Elahe
Publikováno v:
Phytotherapy Research; Aug2019, Vol. 33 Issue 8, p2118-2125, 8p
Publikováno v:
NewsRx COVID-19 Weekly; 4/28/2023, p7-7, 1p